A proof of concept phase II study of Buparlisib in HER2 positive breast cancer with brain metastasis following HER2 directed monoclonal antibody therapy

Trial Profile

A proof of concept phase II study of Buparlisib in HER2 positive breast cancer with brain metastasis following HER2 directed monoclonal antibody therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Buparlisib (Primary)
  • Indications Breast cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms BLUEBELL
  • Sponsors Novartis
  • Most Recent Events

    • 11 Jul 2016 Planned initiation date changed from 1 Jun 2016 to 15 Sep 2016.
    • 26 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top